PTC Therapeutics PTCT is currently in the final 18th phase of its Adhishthana cycle on the weekly chart, and the outlook remains bleak. Signals point to prolonged underperformance, with weakness likely to last through 2030. Here is how the structure unfolds under the Adhishthana framework.

FDA rejects PTC Therapeutics' vatiquinone, citing lack of efficacy for Friedreich's ataxia. After the complete response letter, PTC will discuss the next steps with the FDA. See what Wall Street is buying with instant access to ratings on 1,000 top stocks, including Goldman Sachs, Morgan ...

High-rolling investors have positioned themselves bullish on PTC Therapeutics PTCT, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +22.43% and +4.82%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Sephience is approved for sepiapterin-responsive PKU in patients 1 month and older. Wholesale cost is $40,000 a month; U.S. launch starts in August, targeting 1,200 prescribers. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily. The U.S.